CALL US: +44-208-123-2701   Search: Advanced search Categories Allergies Antidepressants Antineoplastic Antiretroviral Arthritis Asthma Cholesterol Diabetes General Generics Hair Heart Hormones (HRT) Infection Mens Neural Nootropics Skin Thyroid Transgender Ulcer Weight Loss Womens Help About Us Contact us Privacy statement Terms & Conditions FAQ Policies United Pharmacies (UK) :: Antidepressants :: Valdoxan 25mg 28s Valdoxan 25mg 28s Brand Name: Valdoxan Drug Name: agomelatine Other names: Dose: 25mg Form: Film coated Tablets Packaging Type: Box containing 28 25 mg tablets Manufacturer: Servier Country of Origin: Germany Class: Anti-depressant Valdoxan, (active ingredient agomelatine), is the first in a new class of antidepressants called melatonergic agonists. This novel approach to treating depression has many advantages over current treatments. Valdoxan not only works effectively as an antidepressant, it has been shown to improve sleep/wake cycles without causing daytime sleepiness. Additionally, it doesn’t appear to have the side effect of loss of sexual desire or problems with stopping the drug (discontinuation symptoms) that other antidepressants do. Clinical studies have shown that a dose of 25 mg of Valdoxan once daily in the hours before bed effectively treats major depressive disorders. Further studies showed that it works in adults of all ages and in elderly people. Another clinical trial showed that Valdoxan has a similar effectiveness to venlafaxine, which is commonly known as Effexor. Valdoxan interacts with receptors for melatonin and with melatonin antagonist receptors. Scientists believe that the dual action may be responsible for the re-regulation of the sleep/wake cycle. One common problem with traditional treatment of sleep problems that so often go with depression is that treatments left patients somewhat sedated during the daytime. But Valdoxan specifically acts on the wake/sleep cycle, balancing them without making patients sleepy during the daytime. One of the most exciting properties of Valdoxan is that it relieves depression as well as drugs like Effexor and Paxil, but it does not cause loss of sexual function or the discontinuation symptoms that are often associated with SSRI (serotonin specific reuptake inhibitors) antidepressants. A double-blind study of 492 patients with recurring major depressive disorders measured time until relapse and withdrawal due to lack of effectiveness. Valdoxan resulted in a lower relapse rate compared to patients taking a placebo over a six month period. In the placebo group, 46.6% of the patients relapsed over a six month period, whereas in the Valdoxan group, only 21.7% relapsed over the same time period. This pattern held up even in the subpopulation of the study group which had the most severe depression. In a trial comparing Valdoxan with the SSRI sertraline (trade name Zoloft), Valdoxan was found to work better and have a lower rate of discontinuation than sertraline. Valdoxan has also been shown to have anxiolytic, or anxiety-relieving properties, which could make it a useful drug for treatment of anxiety disorders. The most common side effects associated with Valdoxan, seen in between 1% and 10% of patients, are headache, dizziness, sleepiness, insomnia, migraine, nausea, diarrhea, excessive sweating, and increases in anxiety. In some patients, liver enzymes were increased. Most reported side effects were minor and came and went within the first two weeks of treatment. It is possible that some of the reported side effects were linked to depression rather than the drug. Valdoxan should not be used in patients who have liver problems like cirrhosis or active liver disease. It should not be taken by patients who are taking medicines that would slow down the breakdown of Valdoxan such as fluvoxamine (trade name Luvox) and the antibiotic ciprofloxacin (trade name Cipro). It should also not be taken by patients with age related dementia. In January 2009 Valdoxan was granted marketing approval in the European Union for treatment of adult patients with major depression. The drug has not yet attained approval from the U.S. Food and Drug Administration as of mid-2009. Valdoxan was developed by French pharmaceutical company Servier. In the United States, Novartis has exclusive rights to develop and market the drug.   0% Delivery Time: 7-14 Days Options   Price £65.00 Quantity 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 Add to cart              Your cart Cart is empty   View cart Checkout Orders history Authentication Secure login  Register  Recover password If Javascript is disabled in your browser click here

Copyright © 2001-2009 United Pharmacies, Hair Pharmacy All prices are quoted in British Pounds.